Try our Advanced Search for more refined results
Life Sciences - September, 2024
250 articles
- Takeda End Payors, Direct Buyers Win Antitrust Class Cert.
- Wheeling & Appealing: The Latest Must-Know Appellate Action
- Consumer 'Overslept' On Some Drowsy Cough Syrup Claims
- Bristol-Myers Beats Celgene Investors' Drug Delay Suit
- J&J Backs Off 340B Rebate Plan Following Feds' Objections
- Generic-Drug Co. Says To Think Again About 'Double Patenting'
- Allergan Ruling Reinforces Value Of Patent Term Adjustments
- FTC Focus: How Scrutiny Of PBMs And Insulin May Play Out
- Medical Device Co. Wins $25M Verdict In Poaching Trial
- AI May Limit Key Learning Opportunities For Young Attorneys
- J&J Exec Accused Of File Heist Wants Pause Amid DOJ Case
- Kappos' Bayh-Dole Warning To Clients Draws Debate
- 9th Circ. Says Stem Cell Treatment Not Exempt From FDA Rule
- Why Many Drugs Remain Pricey 40 Years After Hatch-Waxman
- Pharma Co. Amarin Beats Class Action Over Patent Issues
- Life Sciences Firms Energize IPO Market As Recovery Builds
- Advil Owner Haleon Paying $637M To Up Stake In China JV
- Medical Equipment Co., Founder Settle FCA Suit For $20M
- SEC Fines Cassava $40M Over Alzheimer's Treatment Claims
- 11th Circ. Affirms Convictions In Fla. Shark Rescue Case
- 2nd Circ. Denies Jury Trial In Abbott Labs Gray Market Case
- New Report Urges Feds To Take Larger Role In Pot Policy
- Walgreens Struggles To Exit 'Non-Drowsy' Label Suit In Wash.
- NC Medical Equipment Maker Can't Ditch Unfair Biz Suit
- Obesity Drug Developer Leads 2 Upsized IPOs Totaling $310M
- Virtua Discriminates Against Pregnant Patients, NJ Alleges
- Senate Patent Bill Markups Delayed Until After Election
- Nobel Winners Behind Gene Editor Seek To Nix Own Patents
- Quest Diagnostics Escapes 401(k) Mismanagement Suit
- In-House Counsel To Play Central Role At AI Cos., VCs Say
- NY Judge Pauses Abortion 'Reversal' Case As AG Files Appeal
- Ascension Must Face Additional Suit Over Vaccine Mandate
- Generics Group Names Ex-BIO, PhRMA Exec As New CEO
- 3rd Circ. Preserves Monsanto's Win In Cancer Warning Suit
- 7th Circ. Judge Surprised Key Argument Left In Footnote
- NJ Pharmacy Execs Cop To $33M Kickback Scheme
- Wyden Pitches New Bill To Regulate Intoxicating Hemp
- DC Circ. Judges Ask If It's Too Late To Fast-Track Gastro Drug
- Expect More R&D Guidance Before Regs, IRS Atty Says
- Cancer Detection Biz To Go Public Via $694M SPAC Merger
- AmerisourceBergen Can't Escape Workers' 401(k) Fee Suit
- Round-Canopy Parachuting Makes Me A Better Lawyer
- And Now A Word From The Panel: The MDL Map
- Google Can't Ditch Privacy Suit Over Period App Data Sharing
- Biotech RenovaCare Investors Seek OK Of $2M Deal
- P&G Says FDA Review Moots Class Suit Over Lead In Tampons
- Philips Must Face Investor Suit Over FDA Compliance Issues
- Buyers Seek $97M Fees From $335M Drug Price-Fixing Deals
- Novo Nordisk Tells Sens. Ozempic Costs Are Linked To PBMs
- Trio Used Penny Stock Co. For Wide-Ranging Fraud, SEC Says
- Moderna Execs Hyped Ineffective RSV Vax, Suit Says
- Navigating Restrictions Following Biotech Bill House Passage
- Firms Allowed To Exit IP Case After Gaining Philips' Consent
- 8th Circ. Won't Revive Pot Shop's Discrimination Suit
- NJ Judge Leaves J&J Ch. 11 Venue Change To Texas Judge
- Why Now Is The Time For Law Firms To Hire Lateral Partners
- J&J Talc Claims Paused In Latest Spinoff Ch. 11
- Mallinckrodt Brass Can't Avoid Investor Suit Over 2nd Ch. 11
- Bio Lab Settles Conn. False-Claims Allegations For $1.73M
- Fired Sotera Exec's Vesting Suit Goes Forward In Del.
- GSK Claims Pfizer Hasn't Proven Misconduct In Vax IP Fight
- Fed. Circ. OKs Novartis Loss In Eye Syringe Patent Feud
- Amneal Latest Generic EpiPen Maker To Fight Colo. Law
- Cancer Test Cos. Strike Deal For Partial End To Patent Row
- A Look At The Economic Impact Of Drug Patent Differentiation
- Insurer Freed From Damaged Blood Plasma Suit
- J&J Accuses Beasley Allen Of Casting Bogus Talc Ballots
- Considering Possible PR Risks Of Certain Legal Tactics
- RSV Vaccine Biz Secures $100M For Series B Funding Round
- Kratom Co. Gets Claims Trimmed In Addiction False Ad Row
- House To Weigh Patent Bill Aimed At Cutting Drug Prices
- ITC Has Been Launching Fewer Section 337 Investigations
- Alnylam Seeks To End Inventorship Suit Tied To COVID Vax
- 3rd Circ. Rejects 'Close' Case For Preemption In Fosamax MDL
- Del. Justices Uphold Toss Of AmerisourceBergen Syringe Suit
- IPO Trio Looks To Raise $536M Combined As Autumn Begins
- DuPont Cos. Can't Escape Cape Fear River PFAS Suit
- Lawmakers Ask USPTO To Fix Patent Calculation Problem
- Plaintiffs Firms Battle Over Proposed $9B Deal In J&J Talc Suit
- Ex-Healthcare Exec Can't Sue GC Over Probe Advice
- J&J Makes Third Try At Handling Talc Claims In Bankruptcy
- It's No Longer Enough For Firms To Be Trusted Advisers
- Cardinal Health Pays $1.12B For Integrated Oncology Network
- Womble Bond Hires New Head Of Int'l Disputes From Dechert
- Ga. Airport Pat-Down Caused Catastrophic Injuries, Man Says
- UK Litigation Roundup: Here's What You Missed In London
- FTC Accuses Drug Middlemen Of Raising Insulin Prices
- Bills On Patent Eligibility, PTAB Limits Near Senate Markup
- AndroGel Antitrust Case On Hold Amid Settlement Talk
- Ga. Appeals Court Says Hospital Must Get Certificate Of Need
- Another Ill. Jury Deadlocks Over Zantac Cancer Claims
- Convicted Drexel Professor Won't Get New Tax Evasion Trial
- Norwich Asks Justices To Allow Sale Of Generic Diarrhea Drug
- Vertex Suit Highlights Issues For Pharma Fertility Support
- Conn. Justices Wonder How 'Malicious' Firm's Ex-Client Was
- Airline Sinks Bias Suit From Worker Fired Over Drug Test
- Axonics Didn't Infringe Medtronic Patents, Calif. Jury Says
- CVS Unit Pays $60M Over Alleged Insurance Kickback Scheme
- 7th Circ. Questions Nixing $183M Eli Lilly Drug Rebate Verdict
- Fed. Circ. Revives Astellas Patent Axed As Natural Law
- Rescheduling Pot Would Not Hasten Research, Report Says
- Georgia High Court Won't Hear Missed Patent Deadline Case
- SEC Settles Latest Covington Info Theft Case For $33K
- Ex-Amgen Rep Wasn't Original Whistleblower, Judge Says
- ITC Looking At Advanced Bionics Implant Patent Claims
- Thermo Fisher Late To Pay Departing Workers, Engineer Says
- GSK Inks 2 Calif. Zantac Deals
- Biotech Co. Escapes Stock-Drop Suit Over COVID-19 Drug
- Organon To Buy Psoriasis Treatment Biz For Up To $1.2B
- Benefit Funds Sue Sandoz Over Alleged Fraudulent Transfers
- CMS' New 'Breakthrough' Device Policy Shows Little Promise
- GC Base Salaries At Big Companies On The Rise
- Philip Morris To Part With Inhaler Maker In Up To £258M Deal
- Express Scripts Blasts 'Biased' FTC Drug Middlemen Report
- Merit Medical To Buy Rival's Heart Implant Biz For $210M
- Teleflex Gets Another Chance In Catheter Patent Feud
- Injectable Analgesic Maker Wants Generic Version Blocked
- Pot Co. Execs Go To 9th Circ. In Investment Scam Case
- 5th Circ. Judge Chides High Court Calls in Abortion Pill Case
- Pall Corp. Shorts Workers By Rounding OT, Suit Says
- J&J Cheers Toss Of 'Indefensible' $260M Talc Verdict
- Bayer Beats IP Firm's Bid To Nix European MRI Patent
- Nebraska Medical Cannabis Initiatives Will Be On Nov. Ballot
- NHS To Pay £87K To Clinician Who Quit Due To Low Funding
- McCarter & English's Misstatement Won't Nix Malpractice Win
- The 2024 Regional Powerhouses
- Sandoz Awarded $137M In Generic Hypertension Drug Fight
- Walgreens To Pay $107M To End 3 False Billing Claims Suits
- Judge Orders Mobile IV Co. To Stop Eli Lilly Infringment
- EU Actors Lobby Hard For Top Jobs in New Commission
- Kennedys Hires Cyber, AI Pro From Addleshaw In London
- New Lessons On Managing Earnout Provision Risks
- 3 Patent Considerations For America's New Quantum Hub
- SEC Fines Zymergen $30M Over Misleading Pre-IPO Claims
- Trio Of BigLaw Mergers Expected To Drive More Deal Talks
- Emergent BioSolutions Pays $40M To Settle COVID Vax Suit
- Med Techs Settle Eyelid Cleaner Patent Spat
- 2 Life Sciences Cos. Start Trading After Raising $540M Total
- Makers Of Paragard Say Time Ran Out On Claims In 236 Suits
- Ex-DOJ Deputy In TikTok, Twitter Cases Joins Mayer Brown
- UK Litigation Roundup: Here's What You Missed In London
- NHS Scotland Sues Accord, Allergan Over Drug Pricing
- Former MilliporeSigma Patent Atty Joins Polsinelli In St. Louis
- Ropes & Gray Helps Kohlberg Net $4.3B For 10th PE Fund
- French Vaccine Maker Valneva Raises €61M In Private Placing
- Alcon Loses European Patent Over Eye Imaging Tech
- A Preview Of AI Priorities Under The Next President
- Wilson Sonsini Hires Tax Pro From Slaughter and May
- Faegre Drinker Adds White Collar Trio From Greenberg Traurig
- Mass Tort Boutique Leader On Sizing Up With Anapol Weiss
- Greenberg Traurig Grows Health Team With Ex-NY Official
- Stites & Harbison Eyes Conn. Office With Patent Team Pickup
- Sullivan & Cromwell Guides Springer Nature's German IPO
- Sanofi Sets €320M Licensing Deal With US, French Biotechs
- Danish Pharma Co. Is Entitled To VAT Reduction
- Litigation Spending To Rise As Cases Grow More Aggressive
- Gender Care Hearing Centers On Ohio Bill Of Rights
- Gov't Spent $236B In Fraud And Improper Payments In 2023
- Top Calif. Biz Bills Sitting On Gov. Newsom's Desk
- How Companies Are Approaching Insider Trading Policies
- 11 Patent Cases To Watch At Fed. Circ. And High Court
- Indivior, Reckitt Benckiser Units Freed From Suboxone MDL
- King & Spalding Adds 4 Attys To Mass Torts Practice In Texas
- Ipsen Exec Made Illegal Trades Before Merger, Feds Say
- Proskauer Lands Fried Frank's Arbitration Head In London
- Phelps Dunbar Recruits 6 Litigators In Raleigh
- Trademarks Surge As UKIPO Transforms Digital Platform
- IP Boutique Hires Murgitroyd Pro For Life Sciences Team
- Dentons Adds 2 Corp. Pros In Dublin From US Rivals
- Sandoz Can't Patent Generic Hypertension Drug
- SEC Files New Insider Case Tied To Stolen Covington Info
- 3rd. Circ. Got It Right On Cancer Warning Claims Preemption
- Neb. Midwife Can't Sue For 'Hypothetical' Clients, Judge Rules
- Cybersecurity Co. Beats Suit Over Med Tech Data Breach
- House Reps. Float Bill To Limit Patent Invalidations
- Philips Balks At Dentons' Request To Exit IP Case
- Free Speech Or Bad Medicine? The Abortion 'Reversal' Battle
- Swedish Biopharma Vicore Announces Plans To Raise $75M
- Cooley Hires Team For Emerging Companies And VC Practice
- Ex-Outcome CEO Says Issues Warrant Bond Pending Appeal
- Pa. Supreme Court Snapshot: Benefits, Cannabis, Taxes
- Exec Denied New Trial In 'Shadow Trading' Case, Fined $321K
- Insurer Needn't Cover Lab Fraud Suits, Ill. Judge Rules
- Ex-Finance Exec To Pay SEC $110K In Insider Trading Action
- Purdue Sees Another OxyContin Patent Axed
- Abbott Says Illinois OT Suit Should Join Similar Case In Ohio
- House OKs Bill To Bar Contracts With Chinese Biotech Cos.
- FTC Backs Teva Orange Book Delisting At Fed. Circ.
- Biotech Execs Face Investor Suit Over Medicare Claims
- Generics Makers Want Mo. Sanctioned In Price-Fixing Case
- To Lower Drug Prices, Harris Must Address Patent Thickets
- MBX Biosciences Seeks Up To $136M In Upcoming IPO
- Baltimore Strikes $80M Opioid Settlement With Teva
- Novo Nordisk Sues Over Ads For Diabetes, Weight Loss Drugs
- Novartis Settles Sales Rep.'s Gender Bias Suit
- How Methods Are Evolving In Textualist Interpretations
- Catching Up With Delaware's Chancery Court
- 2nd Circ. Upholds Regeneron's Win In Remote Work Suit
- Ore. Seeks Dismissal Of Psilocybin Disabilities Suit
- AstraZeneca Unit Owes $130M In Chancery Scuttled-Drug Suit
- Actelion Must Face Tracleer Antitrust Suit With Class Certified
- Biopharm Co., Directors Sued In Del. Over 'Extreme' Scheme
- NJ Medical Co. Claims Ex-Employees Conspired To Form Rival
- Ingersoll Rand Blocks Rival From Hiring Ex-Exec In NDA Fight
- Travel Nurse Says Emory Ended Her Contract Over Race Bias
- Goodwin-Led Cancer Biotech Eyes Roughly $200M IPO
- Glioblastoma Org. Wants End To Rival's Use Of 'GBM'
- Trending At The PTAB: Obviousness In Director Reviews
- Lawmakers, AGs Urge Justices To OK Denial Of E-Cig Apps
- Law Firms Appeal Atty Fee Denial In Opioid Settlements
- Class Attys Vie To Lead Drug Co. Insider Trading Suit In Del.
- Lupin Infringes Exeltis Contraceptive Patents, Judge Finds
- Pharma Co. Verrica Fails To Shed Investor Suit Over FDA OK
- Why Attorneys Should Consider Community Leadership Roles
- Albertsons Denied Texas Court Remand In Opioid MDL
- Leech Tishman Combines With Calif. Firm Nelson Hardiman
- Medical Cos. Must Provide Doctor Names In Fla. Qui Tam Suit
- Bid To Nix Expert Fails As Fed. Circ. OKs $2.3M Patent Verdict
- Ga. Justices Won't Disturb Distributors' Opioid Trial Win
- Groups Urge DC Circ. To Reject Pharma Terrorism Liability Claims
- Zoetis Sanctions Bid Denied In Racehorse Death Suit
- Whittaker Seeks $535M Deal In Talc Cases Tied To Berkshire
- NC Biz Court Bulletin: Blackbeard IP Fight, Firm Data Breach
- Chamber Backs Gilead's Immunity In COVID Appeal
- Agencies Should Reward Corporate Cyber Victim Cooperation
- Glenmark Will Pay $25M To End Feds' Price-Fixing Suit
- McCarter & English Rips Challenge To Malpractice Win In NJ
- Trade Group Urges Court To Toss FDA Lab-Test Rule
- Ga. Justices Affirm Rejection Of Class In Patient Privacy Suit
- Firms Must Offer A Trifecta Of Services In Post-Chevron World
- J&J Hit With $1B Damages In Del. Merger Milestone Fight
- Takeaways From UPC's Amgen Patent Invalidity Analysis
- Arnold & Porter Adds Mintz Healthcare Enforcement Leader
- Louisiana Frees Aurobindo, Sandoz From Price-Fixing Suits
- Teva Investors Get Go-Ahead To Resume Kickbacks Class Suit
- Fed. Circ. Mulls PTAB Ruling's Effect On Liquidia Drug Launch
- Monsanto Keeps Trial Win In Missouri Roundup Cancer Suit
- HQ Specialty Looks To Fix Patent Flaws After Delaware Trial
- Teva Patents Don't Belong In Orange Book, Fed. Circ. Told
- Aesthetic Laser Co. Tells Jury Of Rival's 'Corporate Raid'
- 3rd Circ.: Biotech Must Pay Royalties Despite Expired Patents
- 5 Ways Life Sciences Cos. Can Manage Insider Trading Risk
- Gov't Backs 9th Circ. Bid To Revive Invisalign Monopoly Case
- Aspire Biopharma Inks SPAC Deal At $316M Valuation
- Catching Up With Delaware's Chancery Court
- Scientist Says Yale Medical School Ruined $28M 'Life's Work'
- 5 Tips To Succeed In A Master Of Laws Program And Beyond
- Glenmark Hit With $50M Suit Over Potassium Pill Death
- Semnur Pharmaceuticals To Go Public Via $2.5B SPAC Merger
- Hogan Lovells Tech Transactions Ace Returns To Weil In SF